Determination of plasma β-amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer's disease.
Acridines
/ chemistry
Alzheimer Disease
/ diagnosis
Amyloid beta-Peptides
/ blood
Antibodies, Immobilized
/ immunology
Biomarkers
/ blood
DNA Probes
/ chemistry
DNA, Single-Stranded
/ chemistry
Humans
Immunoassay
/ methods
Limit of Detection
Luminescent Agents
/ chemistry
Luminescent Measurements
/ methods
Nucleic Acid Amplification Techniques
Reproducibility of Results
Alzheimer’s disease
Chemiluminescence immunoassay
Noninvasive diagnostic
Plasma β-amyloid
Rolling circle amplification
Journal
Mikrochimica acta
ISSN: 1436-5073
Titre abrégé: Mikrochim Acta
Pays: Austria
ID NLM: 7808782
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
11
08
2020
accepted:
15
11
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
16
11
2021
Statut:
epublish
Résumé
A rolling circle amplification chemiluminescence immunoassay (RCA-CLIA) was developed for precise quantitation of Aβ in plasma. Capture antibodies conjugated with magnetic beads and detection antibodies with collateral single-stranded DNA (ssDNA) were bound to Aβ42/Aβ40 antigens to form a typical double-antibody sandwich structure. The RCA reaction was triggered by the addition of ssDNA, which generated products with a large number of sites for the binding of acridinium ester (AE)-labeled detection probes, thereby realizing the purpose of the amplification. The RCA-CLIA method had higher sensitivity than conventional CLIA without loss of specificity. Under optimum conditions, the linear range of Aβ42 and Aβ40 detection was 3.9-140 pg/mL and 3.9-180 pg/mL, respectively, with corresponding low detection limits of 1.99 pg/mL and 3.14 pg/mL, respectively. Plasma Aβ42 and Aβ40 were detected in the blood of 21 AD patients and 22 healthy people, wherein this ratio could significantly distinguish AD patients from healthy individuals with a sensitivity of 90.48% and specificity of 63.64% for a cutoff value of 154. The Aβ42/Aβ40 ratio of plasma acts as an accurate indicator for AD diagnosis; therefore, detection of plasma Aβ using the RCA-CLIA exhibits great potential in noninvasive diagnosis and progressive assessment of AD.
Identifiants
pubmed: 33404755
doi: 10.1007/s00604-020-04650-8
pii: 10.1007/s00604-020-04650-8
doi:
Substances chimiques
Acridines
0
Amyloid beta-Peptides
0
Antibodies, Immobilized
0
Biomarkers
0
DNA Probes
0
DNA, Single-Stranded
0
Luminescent Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : the National Natural Science Foundation of China Youth Science Foundation Project
ID : 81802571
Organisme : the National Natural Science Foundation of China Youth Science Foundation Project
ID : 81902156
Organisme : hejiang Medical and Health Science and Technology Project
ID : 2019RC039
Références
Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3(77):77sr71. https://doi.org/10.1126/scitranslmed.3002369
doi: 10.1126/scitranslmed.3002369
Tremblay C, Francois A, Delay C, Freland L, Vandal M, Bennett DA, Calon F (2017) Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 76(2):70–88. https://doi.org/10.1093/jnen/nlw109
doi: 10.1093/jnen/nlw109
pubmed: 28158844
pmcid: 7526851
Tremblay C, Pilote M, Phivilay A, Emond V, Bennett DA, Calon F (2007) Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 12(4):377–390. https://doi.org/10.3233/jad-2007-12411
doi: 10.3233/jad-2007-12411
pubmed: 18198424
Bourassa P, Tremblay C, Schneider JA, Bennett DA, Calon F (2019) Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer’s disease. Acta Neuropathol 137(5):801–823. https://doi.org/10.1007/s00401-019-01967-4
doi: 10.1007/s00401-019-01967-4
pubmed: 30729296
pmcid: 6483878
Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB (2019) Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis. Cell Mol Life Sci 76(10):1833–1863. https://doi.org/10.1007/s00018-019-03040-5
doi: 10.1007/s00018-019-03040-5
pubmed: 30770953
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K (2018) High performance plasma amyloid-beta biomarkers for Alzheimer’s disease. Nature 554(7691):249–254. https://doi.org/10.1038/nature25456
doi: 10.1038/nature25456
pubmed: 29420472
pmcid: 29420472
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ (2019) High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93(17):e1647–e1659. https://doi.org/10.1212/WNL.0000000000008081
doi: 10.1212/WNL.0000000000008081
pubmed: 31371569
pmcid: 31371569
Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K, Fsg SB, Hansson O (2016) CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3(3):154–165. https://doi.org/10.1002/acn3.274
doi: 10.1002/acn3.274
pubmed: 27042676
pmcid: 4774260
Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, Kornhuber J, Morris JC, Fagan AM (2017) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis 55(2):813–822. https://doi.org/10.3233/JAD-160722
doi: 10.3233/JAD-160722
pubmed: 27792012
Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P (2012) Performance of abeta1-40, abeta1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 29(1):229–238. https://doi.org/10.3233/JAD-2011-111349
doi: 10.3233/JAD-2011-111349
Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow KJAon (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58(3):373–379. https://doi.org/10.1001/archneur.58.3.373
Selkoe DJJoAsdJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3(1):75–80. https://doi.org/10.3233/jad-2001-3111
Hardy J, Selkoe DJS (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. https://doi.org/10.1126/science.1072994
Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, Bundo M, Takeda A, Niida S, Ito K, Toba K, Tanaka K, Yanagisawa K (2014) Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci 90(9):353–364. https://doi.org/10.2183/pjab.90.353
doi: 10.2183/pjab.90.353
pubmed: 25391320
pmcid: 4324927
Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ (2017) Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13(8):841–849. https://doi.org/10.1016/j.jalz.2017.06.2266
doi: 10.1016/j.jalz.2017.06.2266
pubmed: 28734653
pmcid: 5567785
Yaka E, Egrilmez MY, Keskinoglu P, Cavdar Z, Genc S, Genc K, Iyilikci L, Yener GG (2009) Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer’s disease. Cell Biochem Funct 27(6):395–401. https://doi.org/10.1002/cbf.1588
doi: 10.1002/cbf.1588
pubmed: 19639578
Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C, Alzheimer’s Disease Neuroimaging I (2016) A potential endophenotype for Alzheimer’s disease: cerebrospinal fluid clusterin. Neurobiol Aging 37:208 e201–208 e209. https://doi.org/10.1016/j.neurobiolaging.2015.09.009
doi: 10.1016/j.neurobiolaging.2015.09.009
Choi C, Jeong JH, Jang JS, Choi K, Lee J, Kwon J, Choi KG, Lee JS, Kang SW (2008) Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer’s disease by color-coded bead technology. J Clin Neurol 4(2):84–88. https://doi.org/10.3988/jcn.2008.4.2.84
doi: 10.3988/jcn.2008.4.2.84
pubmed: 19513308
pmcid: 2686871
Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K (2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res 1362:13–22. https://doi.org/10.1016/j.brainres.2010.09.073
doi: 10.1016/j.brainres.2010.09.073
pubmed: 20875798
Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol 61(2):120–129. https://doi.org/10.1002/ana.21038
doi: 10.1002/ana.21038
pubmed: 17167789
Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL (2008) Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals. Neurochem Res 33(7):1332–1340. https://doi.org/10.1007/s11064-008-9588-x
doi: 10.1007/s11064-008-9588-x
pubmed: 18288611
Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM (2015) The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer’s but not Parkinson’s disease or dementia with Lewy bodies. PLoS One 10(8):e0135458. https://doi.org/10.1371/journal.pone.0135458
doi: 10.1371/journal.pone.0135458
pubmed: 26270969
pmcid: 4536228
Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O (2018) CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91(9):e867–e877. https://doi.org/10.1212/WNL.0000000000006082
doi: 10.1212/WNL.0000000000006082
pubmed: 30054439
pmcid: 6133624
Veloso AJ, Chow AM, Ganesh HV, Li N, Dhar D, Wu DC, Mikhaylichenko S, Brown IR, Kerman K (2014) Electrochemical immunosensors for effective evaluation of amyloid-beta modulators on oligomeric and fibrillar aggregation processes. Anal Chem 86(10):4901–4909. https://doi.org/10.1021/ac500424t
doi: 10.1021/ac500424t
pubmed: 24784791
Fang J, Zhao G, Dong X, Li X, Miao J, Wei Q, Cao WJB, bioelectronics (2019) Ultrasensitive electrochemiluminescence immunosensor for the detection of amyloid-β proteins based on resonance energy transfer between g-CN and Pd NPs coated NH-MIL-53. 142:111517. https://doi.org/10.1016/j.bios.2019.111517
Gu L, Zou Y, Li Y, Zeng K, Zhu N, Zhu F, Gyimah E, Yakubu S, Meng H, Zhang Z (2020) High-throughput chemiluminescence immunoassay based on Co(2+)/hemin synergistic catalysis for sensitive detection tetrabromobisphenol A bis(2-hydroxyethyl) ether in the environments. Sci Total Environ 714:136880. https://doi.org/10.1016/j.scitotenv.2020.136880
doi: 10.1016/j.scitotenv.2020.136880
pubmed: 32018994
Miller SA, Morton MS, Turkes A (1988) Chemiluminescence immunoassay for progesterone in plasma incorporating acridinium ester labelled antigen. Ann Clin Biochem 25(Pt 1):27–34. https://doi.org/10.1177/000456328802500103
doi: 10.1177/000456328802500103
pubmed: 3355086
Schweitzer B, Wiltshire S, Lambert J, O'Malley S, Kukanskis K, Zhu Z, Kingsmore SF, Lizardi PM, Ward DC (2000) Immunoassays with rolling circle DNA amplification: a versatile platform for ultrasensitive antigen detection. Proc Natl Acad Sci U S A 97(18):10113–10119. https://doi.org/10.1073/pnas.170237197
doi: 10.1073/pnas.170237197
pubmed: 10954739
pmcid: 27732
Zhang B, Liu B, Zhou J, Tang J, Tang D (2013) Additional molecular biological amplification strategy for enhanced sensitivity of monitoring low-abundance protein with dual nanotags. ACS Appl Mater Interfaces 5(10):4479–4485. https://doi.org/10.1021/am401027w
doi: 10.1021/am401027w
pubmed: 23593961
Zhang K, Lv S, Lu M, Tang D (2018) Photoelectrochemical biosensing of disease marker on p-type Cu-doped Zn0.3Cd0.7S based on RCA and exonuclease III amplification. Biosens Bioelectron 117:590–596. https://doi.org/10.1016/j.bios.2018.07.001
doi: 10.1016/j.bios.2018.07.001
pubmed: 30005378
Gao M, Lian H, Yu L, Gong M, Ma L, Zhou Y, Yu M, Yan X (2019) Rolling circle amplification integrated with suspension bead array for ultrasensitive multiplex immunodetection of tumor markers. Anal Chim Acta 1048:75–84. https://doi.org/10.1016/j.aca.2018.10.001
doi: 10.1016/j.aca.2018.10.001
pubmed: 30598160
Lu L, Liu B, Zhao Z, Ma C, Luo P, Liu C, Xie G (2012) Ultrasensitive electrochemical immunosensor for HE4 based on rolling circle amplification. Biosens Bioelectron 33(1):216–221. https://doi.org/10.1016/j.bios.2012.01.004
doi: 10.1016/j.bios.2012.01.004
pubmed: 22305445
Zhang K, Lv S, Lin Z, Li M, Tang D (2018) Bio-bar-code-based photoelectrochemical immunoassay for sensitive detection of prostate-specific antigen using rolling circle amplification and enzymatic biocatalytic precipitation. Biosens Bioelectron 101:159–166. https://doi.org/10.1016/j.bios.2017.10.031
doi: 10.1016/j.bios.2017.10.031
pubmed: 29065341
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34(7):939–944. https://doi.org/10.1212/wnl.34.7.939
doi: 10.1212/wnl.34.7.939
pubmed: 6610841
pmcid: 6610841
Shao J, Josephs E, Lee C, Lopez A, Ye TJAn (2013) Electrochemical etching of gold within nanoshaved self-assembled monolayers. ACS Nano 7(6):5421–5429. https://doi.org/10.1021/nn4014005
Bu XL, Xiang Y, Jin WS, Wang J, Shen LL, Huang ZL, Zhang K, Liu YH, Zeng F, Liu JH, Sun HL, Zhuang ZQ, Chen SH, Yao XQ, Giunta B, Shan YC, Tan J, Chen XW, Dong ZF, Zhou HD, Zhou XF, Song W, Wang YJ (2018) Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies. Mol Psychiatry 23(9):1948–1956. https://doi.org/10.1038/mp.2017.204
doi: 10.1038/mp.2017.204
pubmed: 29086767
Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735–741. https://doi.org/10.1126/science.286.5440.735
doi: 10.1126/science.286.5440.735
pubmed: 10531052
Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32(6):1090–1098. https://doi.org/10.1016/j.neurobiolaging.2009.06.002
doi: 10.1016/j.neurobiolaging.2009.06.002
pubmed: 19604603
Ovod V, Ramsey K, Mawuenyega K, Bollinger J, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman D, Morris J, Benzinger T, Fagan A, Patterson B, Bateman RJAs, Association dtjotAs (2017) Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13(8):841–849. https://doi.org/10.1016/j.jalz.2017.06.2266